Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...

A Wenatchee veterans counseling center narrowly avoided a prolonged lapse in services last week after a late-stage contract ...

A federal judge has ruled that The New York Times and other newspapers can proceed with a copyright lawsuit against OpenAI ...

Exelixis, Inc. today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 ...